Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee recommends approval of Selincro for alcohol dependence

Dec. 17, 2012

Vanda's Fanaptum receives negative opinion from EMA

Dec. 17, 2012

EMA committee adopts negative opinion on MAA for Kynamro in HoFH

Dec. 17, 2012

The EMA validates PTC Therapeutics' MAA for ataluren

Dec. 10, 2012

FDA approves Cometriq, EMA accepts MAA

Nov. 30, 2012

EMA recommends granting orphan status to Aspireo's somatoprim

Nov. 26, 2012

EMA to begin formal review of macitentan MAA

Nov. 22, 2012

Zytiga receives positive CHMP recommendation for castration-resistant prostate cancer

Nov. 20, 2012

CHMP recommends Exjade approval for non-transfusion-dependent thalassemia syndromes

Nov. 20, 2012

EMA committee recommends approval of lixisenatide

Nov. 19, 2012

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...